Review of T cell proliferation regulatory factors in treatment and prognostic prediction for solid tumors
Jiayu Li,
Shuhan Ma,
Hongdi Pei,
Jici Jiang,
Quan Zou,
Zhibin Lv
Affiliations
Jiayu Li
Student Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China; College of Life Science, Sichuan University, Chengdu 610065, China
Shuhan Ma
Student Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China
Hongdi Pei
Student Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China
Jici Jiang
Student Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China
Quan Zou
Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 610054, China; Yangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou 324000, China; Corresponding author. Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 610054, China.
Zhibin Lv
Student Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China; Corresponding author.
T cell proliferation regulators (Tcprs), which are positive regulators that promote T cell function, have made great contributions to the development of therapies to improve T cell function. CAR (chimeric antigen receptor) -T cell therapy, a type of adoptive cell transfer therapy that targets tumor cells and enhances immune lethality, has led to significant progress in the treatment of hematologic tumors. However, the applications of CAR-T in solid tumor treatment remain limited. Therefore, in this review, we focus on the development of Tcprs for solid tumor therapy and prognostic prediction. We summarize potential strategies for targeting different Tcprs to enhance T cell proliferation and activation and inhibition of cancer progression, thereby improving the antitumor activity and persistence of CAR-T. In summary, we propose means of enhancing CAR-T cells by expressing different Tcprs, which may lead to the development of a new generation of cell therapies.
